# APOE C112R Research Report

**Protein:** APOE C112R
**Variant:** C112R
**UniProt ID:** P02649
**Disease Association:** Alzheimer's disease
**Report Generated:** 2026-05-26 03:48 UTC
**AlphaFold Confidence (pLDDT):** 71.9%
**Structure Folded:** 2026-05-13

---

## Structure Summary

APOE C112R is a rare genetic variant in apolipoprotein E, a protein that transports cholesterol in the brain and strongly influences Alzheimer's disease risk. AlphaFold2 structural prediction of this variant achieved moderate confidence (average 72%), suggesting the model can predict the overall protein shape but has uncertainty about specific structural details. This variant is classified as a risk factor for Alzheimer's disease by expert panels and has never been observed in healthy populations, indicating it likely increases disease susceptibility through mechanisms that may involve altered cholesterol transport or brain metabolism.

---

Apolipoprotein E (APOE) is a protein critical for transporting cholesterol and other lipids in the brain, and genetic variants of APOE are the strongest known genetic risk factors for late-onset Alzheimer's disease [2][3][5]. The common APOE4 variant dramatically increases Alzheimer's risk through multiple mechanisms including cerebrovascular dysfunction, blood-brain barrier disruption, and metabolic alterations that appear decades before clinical symptoms [3][5]. The C112R variant analyzed here represents a rare mutation where cysteine at position 112 is replaced by arginine, and this variant is classified as a risk factor for Alzheimer's disease by multiple expert submitters to ClinVar, with complete absence from healthy population databases.

The AlphaFold2 structural prediction for APOE C112R achieved a moderate average confidence score of 71.9 pLDDT (predicted local distance difference test), placing it near the threshold that separates reliable predictions (above 70) from uncertain ones (below 70). This intermediate confidence level indicates the model can likely predict the overall protein fold and domain arrangement, but specific local structural details—particularly in flexible or disordered regions—should be interpreted with caution. The cysteine-to-arginine substitution at position 112 represents a dramatic chemical change: cysteine contains a sulfur atom capable of forming disulfide bonds that stabilize protein structure, while arginine is a large, positively charged amino acid that may alter protein folding, stability, or interactions with lipids and cell membranes.

APOE variants exert their effects on Alzheimer's disease through diverse mechanisms beyond simple amyloid accumulation. Research demonstrates that APOE4 exacerbates tau pathology (abnormal protein tangles inside neurons) through mitochondrial dysfunction, particularly under chronic stress conditions [2]. The protein also affects blood-brain barrier integrity, with APOE4 carriers showing increased vascular permeability that may contribute to neurodegeneration [3]. Interestingly, the protective APOE3-Christchurch variant reduces both amyloid and tau pathology when expressed in astrocytes (brain support cells), suggesting that subtle structural differences in APOE can profoundly alter disease progression [1]. Recent evidence indicates that circulating lipid profiles—which APOE directly influences—show disruptions that precede Alzheimer's onset, positioning membrane lipid dysfunction as a primary event rather than a consequence of neurodegeneration [4].

The clinical significance of C112R is underscored by its complete absence from population databases (gnomAD) combined with its classification as a risk factor by expert panels. Variants absent from healthy populations but present in disease cases are highly likely to be pathogenic, as natural selection would eliminate severely harmful mutations from the general population. Given APOE's central role in brain lipid metabolism, cerebrovascular function, and its interactions with both amyloid and tau pathology [2][3][5], the C112R substitution likely disrupts one or more of these critical functions. The moderate structural prediction confidence suggests that while computational modeling provides useful insights into the overall protein architecture, experimental validation through biochemical assays, lipid-binding studies, or cellular models would be necessary to definitively characterize how this specific mutation alters APOE function and contributes to Alzheimer's disease risk.

## Works Cited

[1] Raulin et al. (2026). Astrocytic APOE3-Christchurch expression ameliorates brain amyloid-beta pathology in 5xFAD mice. Translational psychiatry. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41916957/)

[2] Yu et al. (2026). APOE4 exacerbates glucocorticoid stress hormone-induced tau pathology via mitochondrial dysfunction. Cell death & disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41896522/)

[3] Laing et al. (2026). Impact of Apolipoprotein E4 on blood-brain barrier integrity in target replacement murine models: a systematic review and meta-analysis. Alzheimer's research & therapy. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42098772/)

[4] Area-Gomez et al. (2026). Circulating lipids uncover early membrane disruption as a primary event preceding Alzheimer's disease onset. Research square. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42094071/)

[5] Nguyen et al. (2026). A multimodal AI model for modeling the genetic risk factor of Alzheimer's disease. medRxiv : the preprint server for health sciences. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42064906/)


## Similar Research

**Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.**
Ashton et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/)

**Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.**
Sogorb-Esteve et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/)

**Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?**
Ciechanover et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/)

**Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.**
Inigo-Catalina et al. (2025)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/)

**Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.**
Gerlando et al. (2026)
*Relevant to Alzheimer's disease research*
[Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/)

---

## Clinical Data

### ClinVar
- **Classification:** risk factor
- **Review Status:** criteria provided, multiple submitters
- **Last Evaluated:** 2026-01-01

### gnomAD

Not found in gnomAD.

---

## Open Targets Disease Associations

| Disease | Score | Data Sources |
|---------|-------|--------------|
| coronary artery disease | 0.816 | literature, animal_model, genetic_association, genetic_literature |
| hyperlipoproteinemia type 3 | 0.805 | literature, animal_model, genetic_association, genetic_literature |
| lipoprotein glomerulopathy | 0.769 | literature, genetic_association, genetic_literature |
| Alzheimer disease | 0.683 | literature, affected_pathway, rna_expression, genetic_association |
| Sea-blue histiocytosis | 0.637 | literature, genetic_association, genetic_literature |
| age-related macular degeneration | 0.633 | literature, animal_model, genetic_association |
| dementia | 0.631 | literature, genetic_association, genetic_literature |
| familial hypercholesterolemia | 0.625 | literature, animal_model, genetic_association |
| Hypercholesterolemia | 0.611 | literature, genetic_association |
| sea-blue histiocyte syndrome | 0.610 | literature, genetic_association, genetic_literature |

*...and 1606 more associations*

---

## AI Research Brief

# Research Brief: APOE C112R Variant

## Pathogenic Mechanisms

The APOE C112R variant, corresponding to the ε4 allele, represents a critical genetic risk factor for Alzheimer's disease (AD) with well-characterized pathogenic mechanisms. This cysteine-to-arginine substitution at position 112 fundamentally alters the protein's interaction with amyloid-beta (Aβ), enhancing binding affinity and promoting Aβ aggregation—a hallmark of AD pathogenesis. Structurally, the C112R mutation occurs within the lipid-binding domain, potentially disrupting the protein's normal cholesterol transfer activity and acylglycerol homeostasis functions. The variant's pathogenic effects extend beyond direct Aβ interactions, as APOE's known molecular functions include antioxidant activity and regulation of AMPA glutamate receptor clustering, processes critical for neuronal health. The protein's interactions with key partners including LRP1 (involved in Aβ clearance), SNCA (α-synuclein), and complement factor H (CFH) suggest multifaceted mechanisms through which the C112R variant may contribute to neurodegeneration beyond simple amyloid accumulation.

## Clinical Significance

Clinical characterization of APOE C112R carriers is currently in baseline data collection phases, representing a critical gap in understanding this variant's penetrance and phenotypic spectrum. While the ε4 allele is well-established as the strongest genetic risk factor for late-onset AD, systematic documentation of cognitive function trajectories, biomarker profiles (particularly CSF and imaging markers of amyloid and tau pathology), and family history patterns specific to C112R homozygotes remains essential for evidence-based risk stratification. The variant's location in the lipid-binding domain raises questions about broader metabolic consequences beyond neurodegeneration, potentially affecting cardiovascular risk profiles given APOE's central role in lipid metabolism. Establishing baseline characteristics will enable longitudinal studies to differentiate disease progression patterns between C112R homozygotes, heterozygotes, and carriers of protective variants, informing genetic counseling and potentially identifying windows for preventive intervention.

## Therapeutic Landscape

Therapeutic development targeting APOE C112R faces unique challenges given the variant's role as a risk modifier rather than a classical loss-of-function mutation. Aggregation analysis identifies a high-scoring hotspot at residues 6-10 (score: 0.64), leading to the computational design of candidate peptide CP-APOE-001 specifically targeting this N-terminal region. The rationale for targeting residues 6-10 stems from their potential role in pathogenic protein-protein interactions or self-aggregation that may be exacerbated by the C112R substitution's effects on overall protein conformation. However, no experimentally validated peptide inhibitors with published efficacy data (PMIDs) are currently available, representing a significant gap in the therapeutic pipeline. Alternative therapeutic strategies under investigation include small molecules that promote the ε3-like conformation, gene therapy approaches to increase ε2 or ε3 expression, and interventions targeting downstream consequences of impaired cholesterol homeostasis.

## Research Directions

Several actionable research priorities emerge from current knowledge gaps. First, high-resolution structural studies (beyond AlphaFold predictions) comparing C112R to wild-type APOE in complex with Aβ, lipid substrates, and key interacting partners (LRP1, SNCA) would illuminate conformational changes driving pathogenicity. Second, experimental validation of CP-APOE-001 and structure-guided optimization of peptides targeting the 6-10 aggregation hotspot requires prioritization, with particular attention to blood-brain barrier penetration strategies. Third, longitudinal clinical cohorts enriched for C112R homozygotes should assess whether baseline metabolic biomarkers (lipid profiles, glucose metabolism, inflammatory markers) predict cognitive decline trajectories, potentially identifying modifiable risk factors. Finally, investigating whether protective APOE variants or genetic modifiers can compensate for C112R effects could reveal novel therapeutic targets, particularly focusing on pathways regulating antioxidant activity and synaptic function that appear disrupted by this variant.

---

## Agent Findings

### Literature (1)
- **2026-05-13:** No summary generated

### Clinical (1)
- **2026-05-13:** The initiation of baseline data collection for APOE C112R represents a critical first step in establishing the variant's pathogenic potential and clinical penetrance in Alzheimer's disease, as this rare missense mutation in the lipid-binding domain requires systematic documentation of cognitive function, biomarker profiles, and family history to determine its causative role. This baseline characterization will enable clinicians to develop evidence-based risk stratification and potentially inform genetic counseling decisions for carriers, while also providing the foundation for longitudinal studies to track disease progression patterns specific to this variant compared to common APOE alleles.

### Structural (1)
- **2026-05-14:** AlphaFold structure update: Baseline check: 1 structure(s) found

### Synthesis (1)
- **2026-05-14:** Synthesis of 1 findings (peptides): Synthesis JSON could not be parsed; raw response is in agent logs....

---

*Generated by [Clarity Protocol](https://clarityprotocol.io)*

**Data Sources:**
- Structure predictions: AlphaFold via ColabFold
- Clinical variant data: ClinVar, gnomAD
- Disease associations: Open Targets Platform
- Research findings: AI agents (PubMed, clinical databases)